# Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

> **NCT01428063** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 276 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Asunaprevir
- **DRUG:** Pegylated interferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01428063
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2016-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428063, "Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01428063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*